Braveheart Bio, Inc. — Form 8-K

Braveheart Bio, a pre-revenue clinical-stage biopharmaceutical company, completed an IPO in August 2026, issuing 24,437,500 shares at $18.00/share for $439.9M gross proceeds ($404.5M net). Combined with prior Series A financing ($60M for 60M shares at $1.00/share in April 2026), the company has $527.3M pro forma cash as of June 30, 2026, projected to fund operations into 2029. Lead candidate BHB-1893 advanced to Phase 3: LIONHEART-HCM trial initiated in oHCM (first patient expected by year-end 2026, interim results H2 2027), and NOBLEHEART-HCM Phase 3 in nHCM expected H1 2027. Q2 2026 R&D expenses were $11.1M, G&A $4.8M; net loss attributable to common shareholders was $18.6M ($2.51/share).